In addition, crizotinib, the first generation inhibitor for ALK-rearranged NSCLC, demonstrated an overall response rate of 72% as well as a median progression-free survival of 19.2 months in patients with ROS1-rearranged lung cancer7 and was approved as front-line therapy for ROS1-rearranged NSCLC in 2016. Here, ROS1 is linked to non-small cell lung carcinoma.